Tardive and Withdrawal Dyskinesia Associated with Haloperidol
Abstract
Four cases of dyskinesia attributable to treatment with 4-20 mg. of haloperidol daily for more than a year are reported. Two cases involved temporary oral-facial dyskinesias and the others a more persistent complex mixture of neurological features. The possibility that tardive dyskinesia may be associated with the butyrophenones in addition to other antipsychotic agents should be considered, the authors believe.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
